Cox-2 inhibitors and the risk of cardiovascular events

Japan Medical Association Journal

Volumn 49, Issue 7-8, 2006, Pages 276-278

  Hara, Shuntaro ^a   Kudo, Ichiro ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Cardiovascular event; COX 2; Cyclooxygenase; Prostacyclin; Prostaglandin; Tromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; DRUG INDUSTRY; DRUG MARKETING; DRUG STRUCTURE; FEVER; GASTROINTESTINAL DISEASE; HEART INFARCTION; HEART PROTECTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PAIN; PROTEIN SYNTHESIS INHIBITION; STOMACH ULCER; STROKE; STRUCTURE ANALYSIS; THROMBOEMBOLISM; THROMBOSIS;

EID: 37849185845     PISSN: 13468650     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002;53:35-57.
2. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55-80.
3. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
5. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004;177:235-243.
6. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
7. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.